Salvia BioElectronics has raised 26 million euros ($30 million) in new financing to fund development of a neurostimulation therapy for chronic migraine.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.